Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-486 maintenance after subcutaneous azacitidine response in higher-risk elderly MDS
2020-001165-36Phase 2Completed
- Sponsor
- Università degli Studi di Firenze
- Start
- Feb 2021
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CC-486 in myelodysplastic syndrome (MDS), sponsored by Università degli Studi di Firenze. Primary endpoint: Maintenance of response. Started Feb 2021; status: completed.
02
Drugs
CC-486
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2020-001165-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001165-36.